Juan Andres Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) insider Juan Andres sold 15,000 shares of Moderna stock in a transaction on Monday, September 27th. The shares were sold at an average price of $429.38, for a total transaction of $6,440,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Juan Andres also recently made the following trade(s):

  • On Monday, September 27th, Juan Andres sold 15,000 shares of Moderna stock. The stock was sold at an average price of $429.38, for a total value of $6,440,700.00.
  • On Wednesday, September 22nd, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $433.00, for a total value of $2,165,000.00.
  • On Monday, September 20th, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $417.62, for a total value of $2,088,100.00.
  • On Friday, September 17th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $438.24, for a total transaction of $2,191,200.00.
  • On Wednesday, September 15th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $427.13, for a total transaction of $2,135,650.00.
  • On Friday, September 10th, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $461.85, for a total value of $2,309,250.00.
  • On Monday, September 13th, Juan Andres sold 15,000 shares of Moderna stock. The stock was sold at an average price of $447.41, for a total value of $6,711,150.00.
  • On Wednesday, September 1st, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $381.82, for a total transaction of $1,909,100.00.
  • On Friday, August 27th, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $398.12, for a total transaction of $1,990,600.00.
  • On Monday, August 30th, Juan Andres sold 15,000 shares of Moderna stock. The stock was sold at an average price of $368.93, for a total value of $5,533,950.00.

NASDAQ:MRNA traded down $24.63 during midday trading on Tuesday, reaching $384.21. 15,871,461 shares of the stock traded hands, compared to its average volume of 13,531,254. The stock has a market capitalization of $155.08 billion, a PE ratio of 48.55, a price-to-earnings-growth ratio of 0.51 and a beta of 1.48. Moderna, Inc. has a 12-month low of $65.49 and a 12-month high of $497.49. The business has a 50-day moving average of $398.02 and a two-hundred day moving average of $257.78. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.17 and a current ratio of 1.24.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 5th. The company reported $6.46 EPS for the quarter, beating the consensus estimate of $6.01 by $0.45. The firm had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.23 billion. Moderna had a net margin of 49.79% and a return on equity of 88.13%. Moderna’s revenue for the quarter was up 6457.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.31) EPS. Research analysts anticipate that Moderna, Inc. will post 29.13 earnings per share for the current year.

A number of research analysts have weighed in on MRNA shares. Morgan Stanley boosted their price objective on shares of Moderna from $190.00 to $337.00 and gave the company an “equal weight” rating in a research report on Tuesday, September 7th. TheStreet downgraded shares of Moderna from a “b” rating to a “c+” rating in a research report on Friday, June 11th. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Thursday, August 5th. Jefferies Financial Group boosted their price target on Moderna from $170.00 to $250.00 and gave the stock a “hold” rating in a research report on Thursday, July 15th. They noted that the move was a valuation call. Finally, Argus boosted their price target on Moderna from $200.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, June 24th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and an average target price of $205.21.

A number of institutional investors and hedge funds have recently modified their holdings of MRNA. Capital Analysts LLC bought a new stake in Moderna in the first quarter valued at $26,000. Evermay Wealth Management LLC acquired a new stake in shares of Moderna in the second quarter valued at approximately $28,000. Winch Advisory Services LLC increased its stake in Moderna by 1,785.7% during the 2nd quarter. Winch Advisory Services LLC now owns 132 shares of the company’s stock worth $31,000 after acquiring an additional 125 shares during the period. Certified Advisory Corp bought a new position in Moderna during the 1st quarter worth $33,000. Finally, Elmwood Wealth Management Inc. bought a new position in shares of Moderna in the 1st quarter valued at $33,000. 55.89% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Recommended Story: Different Options Trading Strategies

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.